ABSTRACT
Background: The use of nebulizers is an important and useful method for delivering drugs to the lungs in patients with various airway and lung parenchymal disorders. Use of nebulization had markedly increased during the COVID-19 pandemic. This had raised concerns about the potential spread of infection to others in the surroundings exposed to the virus dissemination through aerosolized particles. We considered it necessary to ensure appropriate use of nebulizers by primary care physicians and therefore developed a simple nebulization score to decide when to use nebulizers. Methods: An expert working group (EWG) of pulmonologists was formed who using a semi-Delphi method developed a list of variables and a cut-off score. The EWG started with 55 variables developed through an exhaustive review of literature. These were further reduced to smaller number that had the maximum score as well as concordance with the EWG. The scores ranged from 1-10 (completely disagree to completely agree) and only those above 7.5 were selected. Results: A total of 8 variables with the highest scores were selected [Table 1] which had a total maximum score of 40. A score of <15 was suggested to indicate not-to use and >20 to suggest a definite-use of nebulizer. A score between 15-20 was suggested to use as per physician judgement. A separate table of 12 conditions was made where use of nebulizers was mandatory. Conclusion: This first of its kind nebulizer score should be used by primary care physicians to decide which patients should be put on nebulization treatment.
ABSTRACT
Introduction: Favipiravir has shown promising results for COVID-19 globally. Though many Indian patients have received favipiravir, there is a lack of realworld data for its clinical use by the practicing physicians. Hence, a qualitative survey was conducted to understand real-world use of favipiravir in management of COVID-19. Methods: A cross-sectional, web-based, qualitative survey was conducted between September 2020 to October 2020, among Indian physicians from various specialties involved in COVID-19 care and using favipiravir in their practice. Physicians were provided survey link having a structured questionnaire with 32 questions. They were enquired on- 1) demographics,practice information, 2) place of favipiravir in clinical practice, 3) treatment protocol for mild to moderate COVID-19, 4) dosage and duration of favipiravir, 5) effectiveness of favipiravir, 6) tolerability of favipiravir 7) global efficacy and safety assessment of favipiravir. Results: A total of 500 physicians were contacted, of which 50 physicians completed the questionnaire. 25(50.0%) were from south zone followed by 12(24.0%) from west. . Majority physicians (47, 97.9%) stated that favipiravir was used for COVID-19 in outpatient setting. Favipiravir was considered as the current drug of choice for ' mild COVID-19 with fever(86.6%). All physicians agreed that favipiravir was being used as per the recommended dose.. A total of 75% & 62.5% physicians agreed to observed clinical improvement by around 3-5 days & 5-7 days in symptomatic mild & moderate COVID-19 respectively. Conclusion: Majority of the physicians considered favipiravir to be safe and effective in treatment of mild to moderate COVID-19. © 2021 Journal of Association of Physicians of India. All rights reserved.
ABSTRACT
COVID-19 pandemic caused due to SARS-CoV2 has disrupted the spectrum of health care. The wide arrays of supportive and palliative care needed for patients with ailments were grossly neglected, due to the diversion of resources and healthcare professionals in COVID management. This deficiency was further exaggerated by extended lockdown and closure of outdoor patient care services resulting in unprecedented crisis in disease management. Further, COVID-19 has been associated with increased risk of morbidity and mortality arising from associated risk factors in geriatric subjects and those with other high risk co-morbidities like hypertension, COPD, diabetes and cancer. North East Indian states and the adjoining regions seem to have suffered substantially during the COVID-19 crisis due to their pre-existing vulnerabilities and under developed health care infrastructure and logistics. This deficiency, however, seems to have been fulfilled substantially by the participation of NGO (Non-Government Organizations) and other volunteer services who has actively participated to provide basic healthcare and other life support to cancer patients in this crisis.